Abstract
Human ankyrin repeat and suppressor of cytokine signaling box protein 9 (hASB9), a subunit of an Elongin Ccullin- SOCS box (ECS) E3 ubiquitin ligase complex, is believed to be involved in specific substrate-recognition for ubiquitination and degradation. In fact, this specific substrate-recognition is determined by the ankyrin repeats of hASB9 protein. Here, we have cloned and overexpressed the hASB9-2, the splice variant of hASB9 with only one ankyrin repeat domain, as a 6His-tagged recombinant protein in Escherichia coli. The purified hASB9-2 protein was crystallized by the hanging-drop vapor-diffusion technique and diffracted to 2.2Å resolution. The data showed that the cubic hASB9-2 crystal belongs to space group P4332 with unit-cell parameters (a=b=c=129.25Å, α=β=γ=90°). An asymmetric unit in the crystal was assumed to contain one protein molecule giving the Matthews Coefficient factor of 2.81 and the solvent content of 56.3%.
Keywords: Hasb9, hASB9-2, ankyrin repeat, crystallization, preliminary X-ray analysis
Protein & Peptide Letters
Title: Crystallization and Preliminary X-Ray Analysis of the Splice Variant of Human Ankyrin Repeat and Suppressor of Cytokine Signaling Box Protein 9 (hASB9-2)
Volume: 15 Issue: 6
Author(s): Xiangwei Fei, Yong Zhang, Xing Gu, Rui Qiu, Yumin Mao and Chaoneng Ji
Affiliation:
Keywords: Hasb9, hASB9-2, ankyrin repeat, crystallization, preliminary X-ray analysis
Abstract: Human ankyrin repeat and suppressor of cytokine signaling box protein 9 (hASB9), a subunit of an Elongin Ccullin- SOCS box (ECS) E3 ubiquitin ligase complex, is believed to be involved in specific substrate-recognition for ubiquitination and degradation. In fact, this specific substrate-recognition is determined by the ankyrin repeats of hASB9 protein. Here, we have cloned and overexpressed the hASB9-2, the splice variant of hASB9 with only one ankyrin repeat domain, as a 6His-tagged recombinant protein in Escherichia coli. The purified hASB9-2 protein was crystallized by the hanging-drop vapor-diffusion technique and diffracted to 2.2Å resolution. The data showed that the cubic hASB9-2 crystal belongs to space group P4332 with unit-cell parameters (a=b=c=129.25Å, α=β=γ=90°). An asymmetric unit in the crystal was assumed to contain one protein molecule giving the Matthews Coefficient factor of 2.81 and the solvent content of 56.3%.
Export Options
About this article
Cite this article as:
Fei Xiangwei, Zhang Yong, Gu Xing, Qiu Rui, Mao Yumin and Ji Chaoneng, Crystallization and Preliminary X-Ray Analysis of the Splice Variant of Human Ankyrin Repeat and Suppressor of Cytokine Signaling Box Protein 9 (hASB9-2), Protein & Peptide Letters 2008; 15 (6) . https://dx.doi.org/10.2174/092986608784966859
DOI https://dx.doi.org/10.2174/092986608784966859 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Preface
Current Pharmaceutical Design Genetic Mapping of Pharmacogenetic Regulatory Variation
Current Pharmaceutical Design Hemoglobin Enhances the Biological Activity of Synthetic and Natural Bacterial (Endotoxic) Virulence Factors: A General Principle
Medicinal Chemistry Essential Hypertension: Translating Pathophysiology into Pharmacogenomics
Current Pharmacogenomics Bortezomib in the Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery Molecular Profiles of Sentinel and Non-Sentinel Lymph Nodes in Breast Cancer Progression and Prognosis
Current Cancer Therapy Reviews Involvement of microRNA-146a in the Inflammatory Response of S tatus Epilepticus Rats
CNS & Neurological Disorders - Drug Targets Pandemic of Atopic Diseases - A Lack of Microbial Exposure in Early Infancy?
Current Drug Targets - Infectious Disorders N-Terminal Mutational Analysis of the Interaction Between Growth- Blocking Peptide (GBP) and Receptor of Insect Immune Cells
Protein & Peptide Letters Efficient <i>In Vitro</i> Refolding and Characterization of Major Histocompatibility Complex Class I-Related Chain Molecules A (MICA) and Natural Killer Group 2 Member D (NKG2D) Expressed in <i>E. coli</i>
Protein & Peptide Letters Design and Synthesis of Novel Spiro-Piperidinyl Pyrazolone Derivatives and Their Potential Antiviral Activity
Letters in Drug Design & Discovery Griseofulvin and/or Terbinafine Induced Toxic Epidermal Necrolysis in an Adult Female Patient - A Case Report
Current Drug Safety Use of Naturally Occurring Peptides for Neuropathic Spinal Cord Injury Pain
Current Protein & Peptide Science One-pot, Solvent-free Cascade Michael-reductive Cyclization Reaction for the Synthesis of Ethyl 3,5-disubstituted-1H-pyrrole-2-carboxylates Under Microwave Irradiation
Current Microwave Chemistry Expression and Functions of Galectin-1 in Sensory and Motoneurons
Current Drug Targets Non-viral Gene Delivery and Therapeutics Targeting to Brain
Current Nanoscience The Paradoxical Reaction to Rituximab in Six Granulomatosis with Polyangiitis Patients: How Could it be Explained and Managed?
Current Rheumatology Reviews Polyphenols Beyond Barriers: A Glimpse into the Brain
Current Neuropharmacology New Insights in Drug-Induced Mitochondrial Toxicity
Current Pharmaceutical Design Insulin Therapy and Outcome of Coronavirus Disease 2019 (COVID-19): A Systematic Review, Meta-Analysis, and Meta-Regression
Endocrine, Metabolic & Immune Disorders - Drug Targets